אינג'י 10 מג20 מג טבליות

Kraj: Izrael

Język: hebrajski

Źródło: Ministry of Health

Składnik aktywny:

EZETIMIBE; SIMVASTATIN

Dostępny od:

MERCK SHARP & DOHME ISRAEL LTD

Kod ATC:

C10AA01

Forma farmaceutyczna:

טבליה

Skład:

EZETIMIBE 10 MG; SIMVASTATIN 20 MG

Droga podania:

פומי

Typ recepty:

מרשם נדרש

Wyprodukowano przez:

MERCK SHARP & DOHME (ITALIA) S.P.A.

Grupa terapeutyczna:

SIMVASTATIN

Dziedzina terapeutyczna:

SIMVASTATIN

Wskazania:

Hypercholesterolemia: Inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. Inegy contains ezetimibe and simvastatin. Simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. Studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. Homozygous familial hypercholesterolemia (HoFH): Inegy is indicated as adjunctive therapy to diet for use in patients with HoFH. Patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [LDL] apheresis).

Data autoryzacji:

2012-04-30